The Board of Directors of the Company at the meeting held today approved the Standalone Unaudited Financial Results for the second quarter and half year ended on 30th September 2025 of ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
BDH Industries Ltd announced its Q2 FY26 standalone results on 12 November 2025. Revenue from operations for the quarter rose to ₹1,895.92 lakhs, up about 17% from ₹1,623.22 lakhs in Q2 FY25. Profit after tax for the quarter stood at ₹261.91 lakhs versus ₹240.71 lakhs a year earlier, an increase of roughly 9%. For the half year, revenue grew to ₹3,758.34 lakhs (from ₹3,249.04 lakhs) and PAT improved to ₹444.57 lakhs (from ₹397.56 lakhs). Half-yearly EPS came in at ₹7.72 versus ₹6.91 previously. The Pharmaceuticals segment continues to drive almost all of the business (₹1,875.27 lakhs of ₹1,895.92 lakhs in Q2). Statutory auditor CLB & Associates issued an unmodified limited review report, meaning no qualifications or concerns were raised. The balance sheet remains very strong, with virtually no debt (₹2.81 lakhs in borrowings) and cash and equivalents of ₹3,612.50 lakhs.
Steady mid-teens revenue growth and modest profit expansion, supported by a debt-free balance sheet and clean audit report, suggest stable fundamentals for shareholders. The lack of any strong positive surprise is unlikely to trigger a sharp rally, but the financial health keeps downside risk limited.